Edgewise Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EWTX research report →
About the company
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy.
- CEO
- Kevin Koch
- IPO
- 2021
- Employees
- 117
- HQ
- Boulder, CO, US
Price Chart
- Market Cap
- $4.26B
- P/E
- -23.83
- P/S
- 0.00
- P/B
- 8.59
- EV/EBITDA
- -24.02
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -32.55%
- ROIC
- -40.15%
- Revenue
- $0 · 0.00%
- Net Income
- $-167,795,000 · -25.40%
- EPS
- $-1.63 · -12.41%
- Op Income
- $-191,406,000
- FCF YoY
- -30.34%
- 52W High
- $43.93
- 52W Low
- $12.30
- 50D MA
- $35.01
- 200D MA
- $27.14
- Beta
- 0.30
- Avg Volume
- 1.40M
Get TickerSpark's AI analysis on EWTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 1, 26 | Russell Alan J | other | 69,648 |
| Jul 1, 26 | Russell Alan J | other | 69,648 |
| Jul 1, 26 | Russell Alan J | other | 130,352 |
| Jul 1, 26 | Russell Alan J | sell | 130,352 |
| Jul 1, 26 | Russell Alan J | sell | 69,648 |
| Jul 1, 26 | Russell Alan J | other | 130,352 |
| Jul 1, 26 | Fox Jonathan C | other | 319 |
| Jun 5, 26 | Brege Laura | other | 16,377 |
| Jun 5, 26 | Thompson Peter A. | other | 16,377 |
| Jun 5, 26 | Morris Arlene | other | 16,377 |
Our EWTX coverage
Recent articles, reports, and earnings notes.
No research on EWTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EWTX report →Similar companies
Peers in the same neighborhood.